These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30121425)

  • 1. PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer immunotherapy.
    Ochyl LJ; Bazzill JD; Park C; Xu Y; Kuai R; Moon JJ
    Biomaterials; 2018 Nov; 182():157-166. PubMed ID: 30121425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
    Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
    Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
    Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
    J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination.
    Yang R; Xu J; Xu L; Sun X; Chen Q; Zhao Y; Peng R; Liu Z
    ACS Nano; 2018 Jun; 12(6):5121-5129. PubMed ID: 29771487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
    Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
    J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tumor lysate is an effective vaccine antigen for the stimulation of CD4(+) T-cell function and subsequent induction of antitumor immunity mediated by CD8(+) T cells.
    Kawahara M; Takaku H
    Cancer Biol Ther; 2015; 16(11):1616-25. PubMed ID: 26391871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD40-activated B cells induce anti-tumor immunity in vivo.
    Wennhold K; Weber TM; Klein-Gonzalez N; Thelen M; Garcia-Marquez M; Chakupurakal G; Fiedler A; Schlösser HA; Fischer R; Theurich S; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
    Oncotarget; 2017 Apr; 8(17):27740-27753. PubMed ID: 26934557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
    Aikins ME; Xu C; Moon JJ
    Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Tumor-Peptide-Based Nanoparticle Vaccine Elicits Efficient Tumor Growth Control in Antitumor Immunotherapy.
    Heße C; Kollenda S; Rotan O; Pastille E; Adamczyk A; Wenzek C; Hansen W; Epple M; Buer J; Westendorf AM; Knuschke T
    Mol Cancer Ther; 2019 Jun; 18(6):1069-1080. PubMed ID: 30962317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
    Crosby EJ; Acharya CR; Haddad AF; Rabiola CA; Lei G; Wei JP; Yang XY; Wang T; Liu CX; Wagner KU; Muller WJ; Chodosh LA; Broadwater G; Hyslop T; Shepherd JH; Hollern DP; He X; Perou CM; Chai S; Ashby BK; Vincent BG; Snyder JC; Force J; Morse MA; Lyerly HK; Hartman ZC
    Clin Cancer Res; 2020 Sep; 26(17):4670-4681. PubMed ID: 32732224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses.
    Song S; Jin X; Zhang L; Zhao C; Ding Y; Ang Q; Khaidav O; Shen C
    Int J Nanomedicine; 2019; 14():2465-2483. PubMed ID: 31040669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy.
    Fan Y; Kuai R; Xu Y; Ochyl LJ; Irvine DJ; Moon JJ
    Nano Lett; 2017 Dec; 17(12):7387-7393. PubMed ID: 29144754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy.
    Kuai R; Sun X; Yuan W; Xu Y; Schwendeman A; Moon JJ
    Bioconjug Chem; 2018 Mar; 29(3):771-775. PubMed ID: 29485848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response.
    Yu X; Dai Y; Zhao Y; Qi S; Liu L; Lu L; Luo Q; Zhang Z
    Nat Commun; 2020 Feb; 11(1):1110. PubMed ID: 32111828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.